|
gptkbp:instanceOf
|
gptkb:drug
gptkb:dopamine_antagonist
|
|
gptkbp:approvedBy
|
gptkb:Australia
gptkb:Canada
gptkb:Europe
gptkb:India
gptkb:South_Africa
1978
|
|
gptkbp:ATCCode
|
A03FA03
|
|
gptkbp:brand
|
gptkb:Costi
gptkb:Motilium
Motilidone
|
|
gptkbp:CASNumber
|
57808-66-9
|
|
gptkbp:compatibleWith
|
gptkb:United_States
|
|
gptkbp:contraindication
|
QT prolongation
severe liver impairment
prolactinoma
|
|
gptkbp:discoveredBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:drugClass
|
gptkb:antiemetic
prokinetic agent
|
|
gptkbp:eliminationHalfLife
|
7 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C22H24ClN5O2
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
425.91 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
B1 (Australia)
|
|
gptkbp:proteinBinding
|
91-93%
|
|
gptkbp:PubChem_CID
|
3152
3041
|
|
gptkbp:riskFactor
|
gptkb:arrhythmia
sudden cardiac death
|
|
gptkbp:routeOfAdministration
|
oral
rectal
|
|
gptkbp:sideEffect
|
diarrhea
headache
QT prolongation
dry mouth
abdominal cramps
|
|
gptkbp:UNII
|
Q7Z269A4Y5
|
|
gptkbp:usedFor
|
gptkb:gastroesophageal_reflux_disease
nausea
vomiting
gastroparesis
|
|
gptkbp:bfsParent
|
gptkb:Paul_Janssen
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
domperidone
|